Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly


Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly
Slides from presentations at ASCO 2011 and comments from Susan M O’Brien, MD

Thomas XG et al. Results from a randomized Phase 3 trial of decitabine vs supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. Proc ASCO 2011;Abstract 6504.

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.